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doi:10.1016/j.ejvs.2011.04.030Abstract Background: Patients with critical limb ischaemia (CLI) unsuitable for revasculari-
sation have a high rate of amputation and mortality (30% and 25% at 1 year, respectively).
Localised gene therapy using plasmid DNA encoding acidic fibroblast growth factor (NV1FGF,
riferminogene pecaplasmid) has showed an increased amputation-free survival in a phase II
trial. This article provides the rationale, design and baseline characteristics of CLI patients
enrolled in the pivotal phase III trial (EFC6145/TAMARIS).
Methods: An international, double-blind, placebo-controlled, randomised study composed of
525 CLI patients recruited from 170 sites worldwide who were unsuitable for revascularisation
and had non-healing skin lesions was carried out to evaluate the potential benefit of repeated
intramuscular administration of NV1FGF. Randomisation was stratified by country and by
diabetic status.
Results: The mean age of the study cohort was 70  10 years, and included 70% males and 53%
diabetic patients. Fifty-four percent of the patients had previous lower-extremity revascular-
isation and 22% had previous minor amputation of the index leg. In 94% of the patients, the
index leg had distal occlusive disease affecting arteries below the knee. Statins were
prescribed for 54% of the patients, and anti-platelet drugs for 80%. Variation in region of origin
resulted in only minor demographic imbalance. Similarly, while diabetic status was associated
with a frequent history of coronary artery disease, it had little impact on limb haemodynamics
and vascular lesions.om (E. Van Belle).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
366 E. Van Belle et al.Conclusions: Clinical characteristics and vascular anatomy of CLI patients with ischaemic skin
lesions who were unsuitable for revascularisation therapy show little variations by region of
origin and diabetic status. The findings from this large CLI cohort will contribute to our under-
standing of this disease process.
This study is registered with ClinicalTrials.gov, number NCT00566657.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral artery disease (PAD) is a progressive illness, and
the most severe manifestation is critical limb ischaemia
(CLI).1 An estimated 500e1000 new cases of CLI per million
individuals are diagnosed annually in the USA and Europe.2
These patients experience chronic ischaemic rest pain,
ulcers or gangrene in the lower limbs, and have a very poor
prognosis, with an annual mortality rate of about 20%.1e3
Recommended treatment of the limb is primarily endo-
vascular or open surgical revascularisation.2 However, in
a significant proportion of patients, revascularisation is not
a suitable option or has previously failed. Of these end-
stage patients, 35e50% will require a major amputation
within 12 months,3 since there is no effective pharmaco-
logical option available.4
Therapeutic angiogenesis is a concept based on the use
of angiogenic factors or molecules to promote neo-
vascularisation for the treatment of ischaemic tissues.5
NV1FGF is a recombinant DNA plasmid constructed by
inserting a gene encoding human sp.FGF121e154 into a pCOR
plasmid backbone. The pCOR plasmid backbone ensures
that the plasmids can only replicate in specially engineered
Escherichia coli strains and does not replicate in wild E. coli
strains. This represents a safety advantage, as it limits the
plasmid dissemination to another patient or to the
environment.6,7
Intramuscular administration of NV1FGF in animal models
of hindlimb ischaemia is associated with local expression of
FGF1 for up to several weeks, increased formation of capil-
laries and enlargement of collateral vessels, as well as
increased tissue perfusion.8,9 In a phase II double-blind,
randomised, placebo-controlled, multicenter study
(TALISMAN) including 125 CLI patients with non-healing ulcers
or gangrene and without option for revascularisation, four
administrations of NV1FGF (4 mg) were given at 2-week
intervals. Although it failed to improve ulcer healing, treat-
mentwithNV1FGF demonstrated a 46.3% reduction of the risk
ofmajor amputation (pZ 0.01) anda53% reductionof the risk
of major amputation or death at 12 months (p Z 0.001), as
compared with placebo.10 Other studies based on the same
concept but using different growth factors such as hepatocyte
growth factor (HGF) or vascular endothelial growth factor
(VEGF) failed to demonstratemajor clinical benefit in patient
with peripheral vascular disease.11,12
To confirm and extend the observations from the phase II
trial, a larger international placebo-controlled, double-
blind, randomised phase III trial (TAMARIS) is currently being
performed. The primary objective of this study is to
demonstrate the clinical benefit of NV1FGF (riferminogene
pecaplasmid) in delaying the time to major amputation or
death in CLI patients with non-healing ischaemic skin lesions
who are not candidates for revascularisation. As diabetes
mellitus and country of enrolment could interact with
baseline characteristics of the disease and medicalmanagement,6,13,14 randomisation was stratified according
to these variables.
However, although diabetes mellitus is known to play
a key role in the natural history of atherosclerosis and PAD7
and while geographic differences have been associated
with differences in patients’ characteristics and manage-
ment,14 their impact in patients with CLI is unknown. The
answer to these questions is important to understand the
epidemiology of the disease and to improve the manage-
ment of these patients. Analysis of the baseline data of the
large cohort of CLI patients included in the TAMARIS trial
provides an excellent opportunity to present current key
patient characteristics, including risk factors, co-morbid-
ities, previous history of revascularisation and amputation,
wound care, the extent of arterial lesions and medications.
The worldwide nature of the study, including 525 patients
recruited from 170 sites, allows for description of these
parameters by diabetic status and patient region of origin.
Methods
Patient selection
Recruitment was carried out from December 2007 to July
2009. To be considered as potential candidates for enrol-
ment, patients were required to have CLI with ischaemic
lesions (Fontaine stage IV). The diagnosis had to be
confirmed by at least one haemodynamic measurement
(ankle pressure < 70 mmHg, and/or toe pressure < 50 mmHg
or TcPO2 < 30 mmHg) and by one imaging technique (angi-
ography and Doppler examination). Vascular surgeons had
both to confirm that patients were unsuitable for revascu-
larisation and to justify this decision. The detailed inclusion
and exclusion criteria are described in Supplementary
Tables 1 and 2.
Informed consent procedure and randomisation
Following the attainment of informed consent and
a screening period of 2e8 weeks to allow for verification of
eligibility criteria, patients were randomised using
a central interactive voice response system. Randomisation
was stratified by patient country of origin and by diabetes
status. Separate lists were used for diabetic and non-dia-
betic patients for all centres in each country.
Treatment
Patients were randomly assigned to receive either NV1FGF
(Sanofi-Aventis, Paris, France) or saline as placebo (Sanofi-
Aventis, Paris, France) (Fig. 1). If the disease affected both
Figure 1 Study design of the EFC6145/TAMARIS trial.
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with the lowest pressure index (ankle brachial index, ABI or
toe brachial index, TBI) was designated as the index leg to
be treated. The data of the other leg were recorded in the
case report form (CRF), but not analysed for efficacy. Four
treatment sessions were performed 2 weeks apart over
a period of 6 weeks. At each session, eight intramuscular
injections of 0.5 mg NV1FGF each were administered in the
leg to be treated. Four injections were performed into the
calf muscle and four into the thigh muscle.
Investigators were recommended to follow current
guidelines for optimal medical care of patients. Prostanoids
were to be avoided unless deemed necessary by the clini-
cian during follow-up. Table 4 shows the type and distri-
bution of drug therapy at baseline.Follow-up
All subjects were reviewed at 2, 4 and 6 weeks during the
treatment phase, and then at 3, 6, 9 and 12 months in the
observation phase for assessment of both efficacy and
safety. All adverse events (AEs) and serious adverse events
(SAEs) occurring between randomisation and the patient’s
study end date are being recorded for analysis.Definition of end points
Primary end point
The primary combined end point of the trial is the first
occurrence of either major amputation (above the ankle) of
the treated leg or death from any cause over the 12-month
study period. All amputations are documented by anatomic
level and indication (continuing ischaemia detrimental to
the patient’s health, presence of a lesion considered
unlikely to heal, significant infection/gangrene/osteomye-
litis such that the patient’s life is endangered, intolerable
pain or other cause to be specified).Secondary end point
The main secondary end points are major amputation and
death from any cause over the 12-month study period, ana-
lysed separately. Other criteria include: (1) all amputations,
including all minor and major amputations on the treated
leg; (2) status of skin lesions (worsened, unchanged,
improved or completely healed lesion); (3) pain intensity as
evaluated at rest with a self-administrated visual analogue
scale (VAS); (4) functionality and general health assessment,
including ambulatory function and the residential status for
patients with CLI as investigated by the Deneuville ques-
tionnaire15 and the overall quality of life as evaluated by the
EuroQol questionnaire;16 (5) hospitalisations due to CLI for
amputations, pre-specified main CLI-related events (wors-
ening/increase of ulcers, pain related to PAD, necrosis or
gangrene), complication due to amputation of lower limb,
infection of skin, osteomyelitis, revascularisation, wound
care or further diagnostic procedures; and (6) ABI and TBI
measurements.
Safety
The potential safety concerns associated with growth
factor therapy and systemic exposure include occurrence of
cancer, cardiovascular ischaemic events, occurrence of
active/proliferative retinopathy or neovascularisation and
renal failure.
To exclude any proven or suspected cancer, an extensive
cancer screening was performed for all the patients in this
study. The screening included recording of family history of
cancer, a complete medical examination, chest X-ray, stool
haemocult, haematology blood sampling, PAP smear and
mammography for women, prostrate specific antigen (PSA)
for males, and any additional investigation required by
national guidelines for cancer screening.
An ophthalmic was performed for all patients and
repeated at each.
Myocardial infarction, unstable angina, ischaemic stroke
and acute ischaemia of the lower limbs will be adjudicated
368 E. Van Belle et al.by the Events Adjudication Committee (EAC) for confirma-
tion of diagnosis.
Sample size and strategy for statistical analysis
The sample size calculation for the assessment of efficacy
in this study is based on the previous experience from the
TALISMAN PM201 study where the major amputation event
rate at 1 year was 43% in the placebo group and 22% in the
NV1FGF group, and the death rate before amputation was
equal to 15% in each group.10 Assuming a hazard ratio of
0.558 with a combined event rate (amputation and death)
of 51.5% in the placebo group vs. 33.2% in the NV1FGF
group, a total sample size of 490 patients (245 patients in
each treatment group) was sufficient to provide a power of
90% with a two-sided log rank test at a 5% alpha level, an
expected dropout rate of 5% and a patient follow-up
duration of 12 months.
All efficacy analyses will be based on all randomised
patients, irrespective of whether the patient actually
received the study drug (intention-to-treat population). All
safety analysis will be based on randomised and treated
patients according to treatment actually received (treated
population, intention-to-treat analysis).
Statistical methods
In this baseline paper, data were summarised according to:
diabetic status and region of origin (North America,
Western Europe, Eastern Europe, Asia and Latin America).
For a better understanding of concomitant medication use,
data were also presented according to history of coronary
artery disease (CAD), although this was not a stratification
factor. Since no a priori hypotheses regarding baseline data
were specified in the protocol, no statistical testing was
performed; numerical differences between groups or
regions are, thus, presented descriptively.
Results
Baseline characteristics of the study population
Upon completion of enrolment, 525 patients were rando-
mised in the study. The CONSORT flow chart of the rando-
mised population is presented in Fig. 2.
Baseline patient characteristics are presented in Tables
1e4. Data are presented for the whole population and
according to the two stratification criteria used for ran-
domisation in the study: country (grouped here by
geographic area (North America, Western Europe, Eastern
Europe and Latin America)) and diabetic status. Six patients
recruited in South Africa and 28 recruited in Asia were
omitted from the presentation by geographical area but are
included in the total study population (n Z 525).
Demographic characteristics
Demographic characteristics of the population are presented
in Table 1. Patients enrolled included 70% males and the
group had a mean age of 70 years. There was history ofsmoking (former or current) in 61% and diabetes in 53%, and
18% were currently obese, as defined by body mass index
>30. Hypertension was observed in more than 80% of cases
and hypercholesterolaemia in about 60%. Other manifesta-
tions of atherosclerosis were frequent and included 40% of
patients with a history of CAD and 15% with a history of
stroke. Renal impairment, as estimated by a creatinine
clearance of<50 ml min1, was present in 31%, including 8%
of patients requiring haemodialysis. A history of cancer of
more than 5 years before study entry was found in 6% of the
study patients. Of note, patients with a history of cancer
within the past 5 years were excluded from study entry.
Among regions, a history of CAD was very common in
patients from North America (69%) and relatively rare in
patients from Latin America (16%). Diabetes mellitus was
observed in more than 60% of patients from North America,
Latin America and Asia. As expected, diabetics were more
likely to have characteristics associated with the metabolic
syndrome, including obesity, hyperlipidaemia or hyperten-
sion. A history of CAD (54%) or renal failure (30%) was also
frequently observed in this high-risk population.
Previous management and clinical and functional
status of the index leg
More than 50% of patients had undergone previous revas-
cularisation procedures of the index leg by either angio-
plasty or surgery, and more than 20% had a previous minor
amputation (Table 2). About one-third of the population
had also undergone a previous revascularisation of the
contralateral leg. Additionally, patients who were included
in the study had a major impairment in functional status,
with only 40% patients capable of a daily walking activity or
unassisted physical performance.
Except for a high frequency of previous amputations in
patients from North America (31% vs. the average of 21%),
the previous management and the status of the index leg to
be treated were relatively similar for each of the various
regional areas. Similarly, except for a higher rate of
previous bypass surgery in the non-diabetic population,
there was no major difference in the previous management
and status according to the diabetic status.
Unsuitability for revascularisation was retrospectively
confirmed for 94.6% of patients randomised by the EAC, and
was almost exclusively related to anatomic criteria and an
expected low technical success rate of a revascularisation
procedure (98%). General safety concerns associated with
the procedure in patients with a favourable anatomy were
present in only 2% of cases. No difference was observed
according to geographical area or diabetic status. The high
concurrence rate when confirming unsuitability for revas-
cularisation suggests that the proposed study criteria used
was able to appropriately identify adequate target patients.
Haemodynamic parameters and affected arterial
territories
Almost all patients (96%) met the haemodynamic criteria
defined for study entry (ankle pressure Z 70 mmHg or toe
pressure Z 50 mmHg or TcPO2 < 30 mmHg) (Table 3).
A minority of patients (4%) were enrolled on the basis of
ss
Figure 2 CONSORT flow chart of the study population.
Table 1 Demographic characteristics at study entry e all randomised patients.
All
(N Z 525)
North
America
(N Z 67)
Western
Europe
(N Z 182)
Eastern
Europe
(N Z 179)
Latin
America
(N Z 63)
With
diabetes
mellitus
(N Z 277)
Without diabetes
mellitus
(N Z 248)
Number of patients screened 860 150 308 245 110 NA NA
Sex [n (%)]
Male 365 (69.5%) 42 (62.7%) 136 (74.7%) 138 (77.1%) 31 (49.2%) 197 (71.1%) 168 (67.7%)
Race [n (%)]
Caucasian/White 481 (91.6%) 58 (86.6%) 180 (98.9%) 179 (100%) 61 (96.8%) 249 (89.9%) 232 (93.5%)
Black 12 (2.3%) 8 (11.9%) 1 (0.5%) 0 1 (1.6%) 7 (2.5%) 5 (2.0%)
Asian/Oriental 30 (5.7%) 1 (1.5%) 1 (0.5%) 0 0 21 (7.6%) 9 (3.6%)
Other 2 (0.4%) 0 0 0 1 (1.6%) 0 2 (0.8%)
Age (years) e Mean (SD) 70(9.9) 71.5 (10.1) 72.6 (8.7) 66.6 (9.2) 68.7 (11.7) 70.8 (9.7) 69.1 (10.2)
Smoking status [n (%)]
Never 204 (38.9%) 29 (43.3%) 59 (32.4%) 61 (34.1%) 37 (58.7%) 123 (44.4%) 81 (32.7%)
Former 235 (44.8%) 27 (40.3%) 99 (54.4%) 76 (42.5%) 21 (33.3%) 131 (47.3%) 104 (41.9%)
Current 86 (16.4%) 11 (16.4%) 24 (13.2%) 42 (23.5%) 5 (7.9%) 23 (8.3%) 63 (25.4%)
Hypertension 446 (85.0%) 65 (97.0%) 160 (87.9%) 146 (81.6%) 44 (69.8%) 248 (89.5%) 198 (79.8%)
Hyperlipidaemia 317 (60.4%) 55 (82.1%) 137 (75.3%) 87 (48.6%) 23 (36.5%) 185 (66.8%) 132 (53.2%)
Diabetesa 280 (53.3%) 43 (64.2%) 93 (51.1%) 81 (45.3%) 40 (63.5%) 273a (98.6%) 7a (2.8%)
Associated diseases
Coronary artery disease 235 (44.8%) 47 (70.1%) 91 (50.0%) 71 (39.7%) 10 (15.9%) 151 (54.5%) 84 (33.9%)
Myocardial infarction 130 (24.8%) 27 (40.3%) 52 (28.6%) 37 (20.7%) 5 (7.9%) 87 (31.4%) 43 (17.3%)
Coronary intervention 131 (25.0%) 38 (56.7%) 64 (35.2%) 16 (8.9%) 3 (4.8%) 93 (33.6%) 38 (15.3%)
Congestive heart failure 92 (17.5%) 14 (20.9%) 43 (23.6%) 28 (15.6%) 2 (3.2%) 64 (23.1%) 28 (11.3%)
Stroke 78 (14.9%) 15 (22.4%) 24 (13.2%) 26 (14.5%) 4 (6.3%) 44 (15.9%) 34 (13.7%)
Creatinine clearance group [n (%)]
<30 71 (14.0%) 17 (26.6%) 22 (12.4%) 9 (5.2%) 14 (51.9%) 49 (18.4%) 22 (9.2%)
[30e50] 87 (17.2%) 11 (17.2%) 38 (21.3%) 25 (14.5%) 7 (25.9%) 55 (20.7%) 32 (13.3%)
Chronic renal failure undergoing
haemodialysis
44 (8.4%) 13 (19.4%) 15 (8.2%) 3 (1.7%) 10 (35.7%) 32 (11.6%) 12 (4.8%)
a Diabeteswas a stratification factor. Four non-diabetic patients andfivediabetic patientswere randomised in thewrong stratum in error.
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Table 2 Previous history of revascularization, amputation, and local wound therapy of the Index leg e functional status of the
treated leg. Number (%) e all randomised patients.
All
(N Z 525)
North
America
(N Z 67)
Western
Europe
(N Z 182)
Eastern
Europe
(N Z 179)
Latin
America
(N Z 63)
With
diabetes
mellitus
(N Z 277)
Without
diabetes
mellitus
(N Z 248)
Status of the index leg
Patients with at least
one previous
revascularisation
285 (54.3%) 43 (64.2%) 134 (73.6%) 69 (38.5%) 21 (33.3%) 141 (50.9%) 144 (58.1%)
Peripheral angioplasty 160 (30.5%) 30 (44.8%) 88 (48.4%) 18 (10.1%) 10 (15.9%) 89 (32.1%) 71 (28.6%)
Bypass surgery 191 (36.4%) 23 (34.3%) 88 (48.4%) 57 (31.8%) 16 (25.4%) 82 (29.6%) 109 (44.0%)
Patients with at least
one amputation (minor)
115(21.9%) 21 (31.3%) 42 (23.1%) 33 (18.4%) 14 (22.2%) 68 (24.5%) 47 (19.0%)
Patients with at least
one ischemic/mixed
ulcer or gangrene
524 (99.8%) 67 (100%) 181 (99.5%) 179 (100%) 63 (100%) 276 (99.6%) 248 (100%)
Nb of ulcers/patient [n (%)]
[1e2] ulcers 394 (75.0%) 50 (74.6%) 136 (74.7%) 129 (72.1%) 54 (85.7%) 214 (77.3%) 180 (72.6%)
[3e4] ulcers 64 (12.2%) 8 (11.9%) 27 (14.8%) 19 (10.6%) 3 (4.8%) 36 (13.0%) 28 (11.3%)
5 ulcers 17 (3.2%) 4 (6.0%) 9 (4.9%) 2 (1.1%) 1 (1.6%) 7 (2.5%) 10 (4.0%)
Local wound therapy:
Debridement 131 (25.0%) 12 (17.9%) 32 (17.6%) 78 (43.6%) 5 (7.9%) 77 (27.8%) 54 (21.8%)
Skin graft 1 (0.2%) 1 (1.5%) 0 0 0 1 (0.4%) 0
Other local therapy 318 (60.6%) 33 (49.3%) 116 (63.7%) 106 (59.2%) 42 (66.7%) 163 (58.8%) 155 (62.5%)
Pain VAS (mm)
Mean (SD) 47.81 (25.95) 40.33 (28.48) 45.02 (25.83) 51.60 (24.33) 49.11 (23.72) 45.32 (26.33) 50.59 (25.28)
Median 48.00 44.00 48.00 50.00 50.00 47.00 50.00
Ambulatory function n (%)
Daily walking activity 213 (40.6%) 22 (32.8%) 93 (51.1%) 66 (36.9%) 23 (36.5%) 106 (38.3%) 107 (43.1%)
Walking only inside 210 (40.0%) 32 (47.8%) 56 (30.8%) 91 (50.8%) 21 (33.3%) 108 (39.0%) 102 (41.1%)
Patient confined to a chair 89 (17.0%) 12 (17.9%) 28 (15.4%) 20 (11.2%) 14 (22.2%) 56 (20.2%) 33 (13.3%)
Bedridden 12 (2.3%) 1 (1.5%) 5 (2.7%) 1 (0.6%) 5 (7.9%) 7 (2.5%) 5 (2.0%)
Residential status n (%)
Capable of unassisted
performance
220 (41.9%) 25 (37.3%) 83 (45.6%) 75 (41.9%) 28 (44.4%) 102 (36.8%) 118 (47.6%)
Able to perform personal
hygiene, family
200 (38.1%) 30 (44.8%) 53 (29.1%) 86 (48.0%) 19 (30.2%) 108 (39.0%) 92 (37.1%)
Dependance on family 77 (14.7%) 9 (13.4%) 28 (15.4%) 18 (10.1%) 13 (20.6%) 49 (17.7%) 28 (11.3%)
Dependance on family or
paramedical care
28 (5.3%) 3 (4.5%) 18 (9.9%) 0 3 (4.8%) 18 (6.5%) 10 (4.0%)
370 E. Van Belle et al.a TcPO2 <30 mmHg as single positive haemodynamic test to
meet the inclusion criteria.
Almost all patients (>95%) had infrainguinal arteries
affected by stenosis >70%. Thigh arteries were affected in
two-thirds of the patients, and arteries below the knee
were involved in almost all patients (94%). Furthermore,
multilevel locations of arterial lesions were common and
70% of patients had more than one diseased artery.
These haemodynamic and angiographic patterns were
typically observed in all regional areas, as well as in dia-
betic and non-diabetic patients (Table 3).
Concomitant medications
Cardiovascular drugs were used in more than 80% of
patients, and included b-blockers in 41% and angiotensin-
converting enzyme (ACE) inhibitors in 46%. Lipid-loweringdrugs were used in 60% (56% of those were statins), and
anti-diabetic drugs were used in half of the study pop-
ulation. Anti-platelet agents and anticoagulants were used
in 80% and 35%, respectively. Analgesics were used in about
80% of patients, among which 50% were opioids.
Besides the use of anti-diabetic drugs and of systemic
antibiotics (23%), the diabetic status had very little impact
on the use of concomitant medications (Table 4). There
were, however, variations in the use of some of the medi-
cations according to the presence of CAD and geographical
areas. The presence of CAD was driving the use of some
medications, in particular b-blockers, statins, diuretics and
vitamin K antagonists. The frequent use of these medica-
tions in North America and in Western Europe mirrored the
high prevalence of CAD in these two areas e 69% and 50%,
respectively. Despite a high prevalence of CAD (54%), the
use of these medications in Asia was low.
Table 3 Haemodynamic and angiographic parameters on the treated leg at screening visit e all randomised patients.
All
(N Z 525)
North
America
(N Z 67)
Western
Europe
(N Z 182)
Eastern
Europe
(N Z 179)
Latin
America
(N Z 63)
With
diabetes
mellitusa
(N Z 277)
Without diabetes
mellitusa
(N Z 248)
Patients who met
haemodynamic criterionb
511 (97.3%) 66 (98.5%) 173 (95.1%) 178 (99.4%) 61 (96.8%) 266 (96.0%) 245 (98.8%)
Patients with only
TcPO2<30 mmHg:
c
23 (4.4%) 8 (11.9%) 13 (7.1%) 1 (0.6%) 0 12 (4.3%) 11 (4.4%)
Affected arteries
Suprainguinal arteries 21 (4.0%) 3 (4.5%) 10 (5.5%) 5 (2.8%) 1 (1.6%) 9 (3.2%) 12 (4.8%)
Abdominal aorta 3 (0.6%) 0 1 (0.6%) 0 0 0 3 (1.2%)
Common iliac artery 8 (1.5%) 0 5 (2.8%) 1 (0.6%) 0 3 (1.1%) 5 (2.0%)
External iliac artery 16 (3.1%) 1 (1.5%) 8 (4.4%) 4 (2.2%) 1 (1.6%) 6 (2.2%) 10 (4.0%)
Common femoral artery 18 (3.4%) 3 (4.5%) 7 (3.8%) 5 (2.8%) 1 (1.6%) 8 (2.9%) 10 (4.0%)
Infrainguinal arteries 517 (98.5%) 64 (95.5%) 182 (100%) 177 (98.9%) 61 (96.8%) 272 (98.2%) 245 (98.8%)
Above the knee arteries 354 (67.4%) 42 (62.7%) 117 (64.3%) 132 (73.7%) 39 (61.9%) 174 (62.8%) 180 (72.6%)
Profunda femoris 40 (7.6%) 7 (10.8%) 18 (9.9%) 12 (6.7%) 2 (3.2%) 26 (9.5%) 14 (5.6%)
Superficial femoral artery 286 (54.5%) 30 (44.8%) 103 (56.6%) 112 (62.6%) 25 (39.7%) 129 (46.6%) 157 (63.3%)
Poplitaeal artery 269 (51.3%) 29 (43.9%) 91 (50.0%) 104 (58.1%) 27 (42.9%) 124 (44.9%) 145 (58.5%)
Below the knee 493 (94.1%) 60 (89.6%) 176 (96.7%) 172 (96.1%) 55 (87.3%) 259 (93.8%) 234 (94.4%)
Anterior tibial artery 413 (78.8%) 51 (76.1%) 141 (77.5%) 150 (83.8%) 42 (66.7%) 222 (80.4%) 191 (77.0%)
Posterior tibial artery 442 (84.4%) 52 (77.6%) 157 (86.3%) 158 (88.3%) 45 (71.4%) 230 (83.3%) 212 (85.5%)
Peroneal artery 368 (71.3%) 42 (62.7%) 126 (71.2%) 133 (75.6%) 41 (65.1%) 191 (70.0%) 177 (72.8%)
Dorsalis pedis artery 381 (75.0%) 42 (62.7%) 134 (77.0%) 136 (79.5%) 47 (74.6%) 196 (72.9%) 185 (77.4%)
a Diabetes and country were stratification factors.
b Ankle pressure<70 mmHg and/or Toe pressure<50 mmHg and/or TcPO2 < 30 mmHg.
c Patients in whom TcPO2 <30 mmHg was the only haemodynamic parameter matching the inclusion criteria.
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were mostly not impacted by diabetic status, presence of
CAD or regional area; the only exception being Latin
America, where the use of anti-platelet drugs was rela-
tively low (63%).
No major variation was observed in the use of the other
medications.Discussion
Patients with CLI have a poor natural history and yet no
treatment option beyond revascularisation has shown
a relevant impact on the prevention of amputation and
death. Based on preliminary data,10 therapeutic angiogen-
esis using plasmid DNA encoding for the angiogenic growth
factor FGF1 might provide a new treatment strategy that is
associated with a reduced risk of major amputation or
mortality. The current report on the rationale, design and
baseline characteristics of this pivotal trial on therapeutic
angiogenesis in patients with CLI is important for two main
reasons. First, it demonstrates the feasibility of enrolling
a homogeneous worldwide cohort of patients with end-
stage CLI and no option for revascularisation into a large
clinical trial of gene therapy-based angiogenesis. Second, it
provides important epidemiological insights from a global
perspective and, thus, a unique description of a CLI pop-
ulation that is unsuitable for revascularisation.
Patients enrolledwereprimarily elderly,whitemaleswith
a high burden of cardiovascular risk factors and concomitantcardiovascular diseases. About half of the participants had
diabetes mellitus as a major risk factor. This presented
a challenge to recruit suitable patients, as diabetesmay lead
to chronic and non-healing skin lesions caused by dysfunc-
tions other than ischaemia, such as distal symmetric
neuropathy and neuro-ischaemic combinatorial lesions,
hence the need for objective haemodynamic criteria.
The haemodynamic criteria used for patient selection
with ischaemic ulcers were an ankle pressure ofZ 70 mmHg
or a toe pressure of Z 50 mmHg; these parameters corre-
spond to recommended levels for inclusion in trials and other
scientific purposes according to TASC II.2 We also included
patients with CLI based on toe pressure or TcPO2 in the event
of non-compressible ankle pressures.
As expected, variations between diabetic and non-dia-
betic patients were found to be related to the presence of
certain co-morbidities, including a higher rate of CAD and
heart and renal failure.
The control of risk factors remains suboptimal in
patients with CLI, as illustrated by the general under-
utilisation of statins given the systemic nature of athero-
sclerosis in this population. This was especially true in
patients without established CAD, in whom statins were
used in only 49% as compared to 64% when CAD was known
to be present. These results confirm and extend to the CLI
population the recent observation of the Reduction of
Atherothrombosis for Continued Health (REACH) registry in
which patients with peripheral vascular disease achieved
a suboptimal control of risk factors, including a use of
statins in only 58% of the patients.14 The poor natural
Table 4 Medications at study entry. Number (%) of patients with at least one specific medication at study entry e all rand-
omised patients.
Total
(N Z 525)
North
America
(N Z 67)
Western
Europe
(N Z 182)
Eastern
Europe
(N Z 179)
Latin
America
(N Z 63)
With diabetes
mellitus
(N Z 277)
Without
diabetes
mellitus
(N Z 248)
Concomitant medications at
study entry
521 (99.2%) 67 (100%) 182 (100%) 175 (97.8%) 63 (100%) 277 (100%) 244 (98.4%)
Cardiovascular 428 (81.5%) 65 (97.0%) 167 (91.8%) 128 (71.5%) 42 (66.7%) 239 (86.3%) 189 (76.2%)
Beta blockers 217 (41.3%) 44 (65.7%) 87 (47.8%) 62 (34.6%) 15 (23.8%) 130 (46.9%) 85 (34.3%)
ACE-inhibitors 240 (45.7%) 36 (53.7%) 88 (48.4%) 90 (50.3%) 20 (31.7%) 128 (46.2%) 111 (44.8%)
Diuretics 225 (42.9%) 34 (50.7%) 102 (56.0%) 59 (33.0%) 21 (33.3%) 134 (48.4%) 89 (35.9%)
CA antagonists 148 (28.2%) 25 (37.3%) 58 (31.9%) 38 (21.2%) 13 (20.6%) 81 (29.2%) 67 (27.0%)
Angiotensin II antagonists 90 (17.1%) 13 (19.4%) 43 (23.6%) 15 (8.4%) 11 (17.5%) 58 (20.9%) 32 (12.9%)
Other anti-hypertensives 45 (8.6%) 12 (17.9%) 16 (8.8%) 9 (5.0%) 7 (11.1%) 28 (10.1%) 17 (6.9%)
Lipid lowering drugs 310 (59.0%) 50 (74.6%) 140 (76.9%) 89 (49.7%) 20 (31.7%) 169 (61.0%) 142 (57.3%)
Statins 295 (56.2%) 45 (67.2%) 134 (73.6%) 85 (47.5%) 20 (31.7%) 160 (57.8%) 135 (54.4%)
Other lipid lowering drugs 36 (6.9%) 10 (14.9%) 15 (8.2%) 11 (6.1%) 0 24 (8.7%) 13 (5.2%)
Hypoglycemic drugs 266 (50.7%) 40 (59.7%) 86 (47.3%) 79 (44.1%) 39 (61.9%) 261 (94.2%) 5 (2.0%)
Insulin 154 (29.3%) 22 (32.8%) 54 (29.7%) 49 (27.4%) 21 (33.3%) 151 (54.5%) 3 (1.2%)
Oral hypoglycemics 147 (28.0%) 25 (37.3%) 44 (24.2%) 39 (21.8%) 25 (39.7%) 145 (52.3%) 2 (0.8%)
Antiplatelets 423 (80.6%) 56 (83.6%) 150 (82.4%) 148 (82.7%) 40 (63.5%) 222 (80.1%) 201 (81.0%)
Anticoagulants 183 (34.9%) 15 (22.4%) 95 (52.2%) 41 (22.9%) 14 (22.2%) 98 (35.4%) 84 (33.9%)
Systemic antibiotherapy 122 (23.2%) 11 (16.4%) 55 (30.2%) 30 (16.8%) 17 (27.0%) 78 (28.2%) 43 (17.3%)
Analgesics 436 (83.0%) 58 (86.6%) 155 (85.2%) 143 (79.9%) 50 (79.4%) 222 (80.1%) 211 (85.1%)
Non opioids 370 (70.5%) 47 (70.1%) 124 (68.1%) 129 (72.1%) 47 (74.6%) 188 (67.9%) 178 (71.8%)
Weak opioids 187 (35.6%) 31 (46.3%) 65 (35.7%) 49 (27.4%) 20 (31.7%) 92 (33.2%) 93 (37.5%)
Strong opioids 88 (16.8%) 17 (25.4%) 49 (26.9%) 14 (7.8%) 3 (4.8%) 41 (14.8%) 46 (18.5%)
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under-treatment with anti-platelet drugs and other risk
modifying therapies. However, while it has been suggested
that secondary prevention may be less frequently applied in
diabetic than in non-diabetic patients,17 our data show that
this is not the case at that relatively late stage of the
disease with a use of b-blockers in 47% of the cases (vs. 34%
in non-diabetic patients), statins in 58% of the cases (vs.
54% in patients without diabetes) and of anti-platelet drugs
in 80% of the cases (vs. 81% in patients without diabetes).
Regional variation in patient demographicswas rare. They
were mainly related to the prevalence of some risk factors,
as illustrated by a high rate of diabetes mellitus in North
America and South America, of CAD inWestern countries and
Asia. These variations were responsible for most of the
observed variation in the use of medication among regions.
The most noticeable were the low use of previous revascu-
larisation of the index leg in Eastern Europe and Latin
America (<40%) compared to other regions (>60%) and the
lowuse of statins (26%) in Latin America as compared to other
countries with a high prevalence of CAD, such as North
America (52%) or Western Europe (68%).
These findings suggest that in non-reconstructable CLI,
the clinical, haemodynamic and anatomical presentation
are homogeneous and independent of a major risk factor,
such as diabetes, and patients are basically treated with
only small variation between the countries.The little variations among the studied population that
was recruited based on simple haemodynamic parameters is
important in the light of the interpretation of the present
trial and demonstrates that the CLI population can be
considered globally. This observation is also important for
the design of future phase III trials to test the benefit of gene-
based or cell-based angiogenic therapies in patientswithCLI.
Limitations
The fact that patients were selected as part of a rando-
mised trial may have impacted the results and could limit
the ability to generalise the observations to patients with
CLI in general. Similarly, the absence of formal statistical
comparison decreases our ability to detect small differ-
ences among groups.
Conclusions
Diabetic status and regional origin are important factors of
variations in patients with PAD. However, their impact in
patients with CLI is unknown. TAMARIS is the largest trial in
patients with non-reconstructable CLI with skin lesions (Fon-
taine stage IV). The analysis of the baseline characteristics of
the population included in the present study showed that at
this stage of the disease, the population can be considered
Role of Diabetes and Geographic Variation on Characteristics and management of patients with CLI 373with little variations in terms of arterial lesions and manage-
ment according to regional origin and diabetic status. This
observation is important for the overall understanding of this
disease. It will also have to be taken into account for the
design of future trials in this patient population.
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